|
業務類別
|
Biotechnology |
|
業務概覽
|
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy. |
| 公司地址
| 20 William Street, Suite 145, Wellesley Hills, MA, USA, 02481 |
| 電話號碼
| +1 866 857-2596 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.climbbio.com |
| 員工數量
| 29 |
| Dr. Susan Altschuller, M.B.A.,PhD |
Chief Financial Officer and Treasurer |
-- |
01/10/2025 |
| Dr. Aoife M. Brennan, M.D. |
President, Chief Executive Officer and Director |
美元 330.00K |
01/10/2025 |
| Ms. Cindy Driscoll |
Senior Vice President, Finance and Principal Accounting Officer |
-- |
01/10/2025 |
|
|
| Dr. Judith A. Dunn, PhD |
Independent Director |
25/04/2025 |
| Dr. Kimberlee Cobleigh Drapkin, PhD |
Director |
01/04/2025 |
| Dr. Douglas E. Williams,PhD |
Chairman of the Board |
25/04/2025 |
| Dr. Aoife M. Brennan, M.D. |
President, Chief Executive Officer and Director |
01/10/2025 |
| Mr. Alexander G. Cumbo |
Director |
01/04/2025 |
| Dr. Stephen Thomas, PhD |
Independent Director |
25/04/2025 |
| Dr. Andrew Levin, M.D.,PhD |
Director |
25/04/2025 |
|
|
|
|
